Product Description
Lopinavir
Lopinavir
192725-17-0
Lopinavir is an antiretroviral protease inhibitor used in combination with ritonavir in the therapy and prevention of human immunodeficiency virus (HIV) infection and the acquired immunodeficiency syndrome (AIDS).
Recent studies have shown molnupiravir inhibits replication of human and bat coronaviruses, including SARS-CoV-2, in mice and human airway epithelial cells.
AI Product Description
*The following content is generated by AI and is for reference only.
Lopinavir is a potent antiretroviral medication classified as a protease inhibitor, primarily utilized in the management of Human Immunodeficiency Virus (HIV) infection. Its chemical identity is defined by the molecular formula C37H48N4O5 and it is registered under the CAS number 192725-17-0. This compound functions by specifically inhibiting the HIV-1 protease enzyme, which is essential for the viral replication cycle. By blocking this enzyme, Lopinavir prevents the cleavage of viral polyproteins into functional units, thereby producing immature, non-infectious viral particles. Due to its mechanism of action, Lopinavir is almost exclusively administered in combination with another protease inhibitor, ritonavir, which acts as a pharmacokinetic booster. Ritonavir inhibits the cytochrome P450 3A4 enzyme system, significantly increasing plasma concentrations of Lopinavir and extending its half-life, allowing for less frequent dosing and improved therapeutic efficacy.
Clinically, Lopinavir/ritonavir is a cornerstone in highly active antiretroviral therapy (HAART), used to suppress viral load and restore immune function in patients with HIV-1. It is indicated for both treatment-naïve individuals and those who have failed previous regimens, provided the virus retains susceptibility. The drug is available in oral formulations, including tablets and an oral solution, facilitating flexible administration for various patient demographics, including children. While generally well-tolerated, common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal pain, alongside potential metabolic abnormalities like hyperlipidemia and hyperglycemia. Long-term monitoring of lipid profiles and glucose levels is often recommended during therapy. Furthermore, Lopinavir exhibits significant drug-drug interaction potential due to its metabolism via hepatic enzymes, necessitating careful review of concomitant medications. As a critical component of global HIV treatment protocols, Lopinavir has played an indispensable role in transforming HIV from a fatal diagnosis into a manageable chronic condition, contributing substantially to increased life expectancy and quality of life for millions of patients worldwide.